Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 7, 1999, Pages 1640-1649

  Southgate, Kay M ^a   Mehta, Dheeraj ^a   Izzat, Mohammed B ^a   Newby, Andrew C ^a   Angelini, Gianni D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cell proliferation; Gelatinases; Vascular smooth muscle; Vein grafts

Indexed keywords

GELATINASE A; GELATINASE B;

ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; ARTICLE; BASEMENT MEMBRANE; BYPASS SURGERY; CAROTID ARTERY SURGERY; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVITY; GRAFT FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SAPHENOUS VEIN GRAFT; SWINE; VASCULAR SMOOTH MUSCLE; ZYMOGRAPHY;

EID: 0033001718     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.7.1640     Document Type: Article

References (49)

1. Izzat MB, Angelini GD. Arterial conduits in myocardial revascularization. Surgery. 1994;12:37-41.
2. Kraiss L, Clowes A. Vascular grafts and their sequelae. In: Fuster VRR, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996;1:727-737.
3. Angelini GD, Newhy AC. The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J. 1989;10:273-280.
4. Cox J, Chiasson D, Gotlieb A. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis. Prog Cardiovasc Dis. 1991;34:45-68.
5. Fremes S, Levinton C, Naylor C, Chen E, Christakis G, Goldman B. Optimal antithrombotic therapy following aortocoronary bypass: a meta analyses. Eur J Cardiothorac Surg. 1993;7:169-180.
6. Angelini GD, Bryan AJ, Williams HMJ, Soyombo AA, Williams A, Tovey J, Newby AC. Time-course of medial and intimai thickening in pig venous arterial grafts: relationship to endothelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg. 1992;103:1093-1103.
7. Newby AC, George SJ. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc Res. 1993;27:1173-1183.
8. Francis SE, Hunter S, Holt CM, Gadsdon PA, Rogers S, Duff GW, Newby AC, Angelini GD. Release of platelet-derived growth factor activity from pig venous arterial grafts. J Thorac Cardiovasc Surg. 1994;108:540-548.
9. George SJ, Williams A, Newhy AC. An essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. Atherosclerosis. 1996;120:227-240.
10. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN, Schwartz SM. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990;111:2149-2158.
11. Ferns GAA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-1132.
12. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscler Thromb. 1993;13:1218-1226.
13. Soyombo AA, Angelini GD, Bryan AJ, Newby AC. Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc Res. 1993;27:1961-1967.
14. Campbell JH, Black MJ, Campbell GR. Replication of smooth muscle cells in atherosclerosis and hypertension. In: Meyer P, Marche P, eds. Blood Cells and Arteries in Hypertension and Atherosclerosis. New York. NY: Raven Press; 1989;15-33.
15. Hedin U, Bottger BA, Forsberg E, Johansson S, Thyberg J. Diverse effects of fibronectin and laminin on phenotypic properties of cultured smooth muscle cells. J Cell Biol. 1988;107:307-319.
16. Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J. 1992;288:93-99.
17. Newby AC, Fabunmi RP, George SJ, Southgate KM, Banning AP, Thurston VJ, Williams A. Neointimal fibrosis in vascular pathologies: role of growth factors and metalloproteinases in vascular smooth muscle proliferation. Exp Nephrol. 1995;3:108-113.
18. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
19. Galis ZS, Muszynski M, Sukhova GK, Simon-Morissey E, Uncmori E, Lark MW, Amento E, Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of extracellular enzymes required for extracellular matrix degradation. Circ Res. 1994;75:181-189.
20. Fabunmi RP, Baker AH, Murray EJ, Booth RFC, Newby AC. Divergent regulation by growth factors and cytokines of 95-kDa and 72-kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
21. Zempo N, Koyama N, Kenagy R, Lea H, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28-33.
22. Zempo N, Kenagy RD, Au T, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg. 1994;20: 209-217.
23. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78:38-43.
24. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
25. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH, Fabunmi RP, Groves PH, Davies M, Newby AC. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 1996;79:1177-1187.
26. George SJ, Zaltsman AB, Newby AC. Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res. 1997;33:447-459.
27. Angelini GD, Bryan AJ, Williams HMJ, Morgan R, Newby AC. Distention promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg. 1990;99:433-439.
28. Galand P, Degraef C. Cyclin/PCNA immunostaining as an alternative to tritiated thymidine pulse labelling for marking S-phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 1989;22: 383-392.
29. Izzat MB, Mehta D, Bryan AJ, Reeves B, Newby AC, Angelini GD. Influence of external stent size on early medial and neointimal thickening in a pig model of saphenous vein bypass grafting. Circulation. 1996;94: 1741-1745.
30. Gown AM, Tsukada T, Ross R. Human atherosclerosis: immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. Am J Pathol. 1986;125:191-207.
31. Roussel F, Dalion J. Lectins as markers of endothelial cells: comparative study between human and animal cells. Lab Anim. 1988;22:135-140.
32. Mehta D, George SJ, Jeremy JY, Izzal MB, Southgate KM, Bryan AJ, Newby AC, Angelini GD. External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nature. 1998;4:235-239.
33. Zaltsman AB, Newby AC. Increased secretion of gelatinase A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Atherosclerosis. 1997;130:61-70.
34. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994;370:61-65.
35. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kD type IV collagenase: isolation of the activated form of the membrane metalloproteinase. J Biol Chem. 1995;270:5331-5338.
36. Lichte A, Kolkenbrock H, Tschesche H. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2. FEBS Lett. 1996;397:277-282.
37. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
38. Huhtala P, Tuuttila A, Chow LT, Lohi J, Keski-Oja J, Tryggvason K. Complete structure of human gene for 92-kDa type IV collagenase: divergent regulation of expression for the 92-and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem. 1991;266:16485-16490.
39. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther. 1998;9:867-877.
40. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996;79:812-820.
41. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of matrix metalloproteinase-1. -2. or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation and death in vitro. J Clin Invest. 1998;101:1478-1487.
42. Pauly PR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT. Migration of cultured vascular smooth muscle cells through basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994;75:41-54.
43. Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch DH, Stetler-Slevenson WG, Oyasu R. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer. 1995;63:568-575.
44. Talbot D, Brown P. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer. 1996;32:2528-2533.
45. Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ. Phase I trial of a novel matrix metalloproteinase inhibitor batimastal (BB94) in patients with advanced cancer. Invest New Drugs. 1996;14:193-202.
46. Wojtowiez-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ. Phase 1 trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998;16:2150-2156.
47. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol. 1998;45:21-26.
48. Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohlani M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem. 1998;41:640-649.
49. Levy DE, Ezrin AM. Matrix metalloproteinase inhibitor drugs. Emerg Drugs. 1997;2:205-230.